Mathew Maurer
Columbia University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mathew Maurer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05635045 · Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTRColumbia University · completed · Transthyretin Amyloidosis · principal investigator
- Ph4NCT05233163 · SGLT2 Inhibitors in Transthyretin Amyloid CardiomyopathyColumbia University · completed · Transthyretin Amyloid Cardiomyopathy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac AmyloidosisR01AG081582 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2023 to 2026 · $688,635 awarded in 2026Same name and institution; not confirmed by an ID
- SCAN-MP (Screening for Cardiac Amyloidosiswith Nuclear imaging in Minority Populations)R01HL139671 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2019 to 2023 · $1,464,245 awarded in 2023Same name and institution; not confirmed by an ID
- Midcareer Mentoring Award for Patient Oriented Research in Geriatric CardiologyK24AG036778 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2010 to 2020 · $157,032 awarded in 2020Same name and institution; not confirmed by an ID
- Analysis of Lumbar Spine Stenosis Speciments for Early Identification of TTR Cardiac AmyloidosisR21AG058348 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2018 to 2019 · $201,323 awarded in 2019Same name and institution; not confirmed by an ID
- Can Ventricular Assist Devices Reverse the Frailty PhenotypeR21AG046703 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2014 to 2015 · $224,686 awarded in 2015Same name and institution; not confirmed by an ID
- DASH-SRD Post Acute Decompensated Heart Failure HospitalizationR21AG047939 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2014 to 2015 · $217,364 awarded in 2015Same name and institution; not confirmed by an ID
- Pathophysiology of Heart Failure with a Normal Ejection Fraction in the ElderlyR01AG027518 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2007 to 2010 · $531,384 awarded in 2010Same name and institution; not confirmed by an ID
- Cardiovascular Causes of Falls/Syncope in the ElderlyK23AG000966 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2001 to 2005 · $128,817 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:47 UTC. The ranking covers the 200 most relevant of 260 PubMed records, and a shared surname and initials can bring in a namesake. All 260 on PubMed
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.N Engl J Med · 20182,317 citationsRCR 92.6
- 1,521 citationsRCR 81.5
- Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.N Engl J Med · 2013826 citationsRCR 29.1
- Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.J Clin Oncol · 2005574 citationsRCR 11.8
- Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.N Engl J Med · 2024482 citationsRCR 76.5
- Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.N Engl J Med · 2010447 citationsRCR 13.8
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.J Allergy Clin Immunol · 2013424 citationsRCR 15.8
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.N Engl J Med · 2025391 citationsRCR 108.0
- The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience.JACC Cardiovasc Interv · 2012381 citationsRCR 13.4
- Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.Circulation · 2019379 citationsRCR 15.2